Roundhill Glp-1 & Weight Loss ETF OZEM
Set alert
At close · Oct 30
After hours · Oct 30, 4:00 PM ET
- YTD
- -10.14%
- 1 year
- +9.08%
- Open
- 30.75
- Prev close
- 30.29
- Mkt cap
- 39.00M
- Vol
- 20.54K
- Avg vol
- 15.25K
- EPS
- 1.66
- P/E
- 18.46
- Div yield
- 0.00%
More statistics
- Low
- 30.56
- High
- 30.86
- Forward P/E
- 0.00
- Beta
- 0.00
- Short ratio
- 0.00
- Dividend
- 0.00
- Ex-div date
- 50-d avg
- 26.99
- 200-d avg
- 27.14
News
1 week ago zacks.com
Obesity ETFs to Gain as Novo's CagriSema Shows 25% Weight Loss
Novo Nordisk's CagriSema delivers 25% weight loss in women, spotlighting three ETFs for diversified exposure to the sector's growth.
1 week ago zacks.com
Bet on This New GLP-1 ETF to Gain Exposure to a Booming Market
REX Shares recently launched the REX Peptide ETF (PEPT), a thematic fund offering global exposure to the peptide industry, from drug developers to manufacturers and delivery platforms.
2 weeks ago defenseworld.net
Roundhill GLP-1 & Weight Loss ETF (NASDAQ:OZEM) Stock Price Down 0.6% – Time to Sell?
Shares of Roundhill GLP-1 and Weight Loss ETF (NASDAQ: OZEM - Get Free Report) dropped 0.6% during trading on Wednesday. The company traded as low as $28.34 and last traded at $28.73. 7,410 shares…
2 weeks ago etftrends.com
From Laggard to Leader: The Surprising Comeback of Healthcare
Healthcare stocks have finally stepped back into the spotlight. After spending much of the past several years in the shadow of technology and AI, the sector has quietly emerged as one of the year's…
1 month ago zacks.com
Lilly vs. Novo: Inside the Milan EASD Showdown and the ETFs Poised to Win
LLY and Novo face off at EASD as new data fuels the GLP-1 market, while ETFs offer diversified exposure to weight loss drug growth.
2 months ago defenseworld.net
Roundhill GLP-1 & Weight Loss ETF (NASDAQ:OZEM) Shares Down 0.4% – Time to Sell?
Roundhill GLP-1 and Weight Loss ETF (NASDAQ: OZEM - Get Free Report)'s share price dropped 0.4% during trading on Tuesday. The company traded as low as $33.64 and last traded at $33.68. 17,650 shares…
4 months ago zacks.com
Weight Loss ETFs Poised to Rally as Medicare Greenlights GLP-1 Coverage
Medicare's new GLP-1 coverage could expand access to weight-loss drugs, making ETFs a diversified way to tap growth across the obesity treatment market.
4 months ago etftrends.com
Healthcare ETFs: From Broad Exposure to Big Breakthroughs
With AI and space dominating many of the market's most popular investment themes, it can be difficult to find differentiated opportunities. Healthcare is often viewed as one of the more defensive…
4 months ago zacks.com
Inside the GLP-1 Boom: ETF Picks for the Obesity Drug Market
GLP-1 drugs are reshaping healthcare and consumer markets. These ETFs offer targeted exposure to the booming obesity-drug trend.
5 months ago zacks.com
GLP-1 Drug Giants Race to Go Global With Their Obesity Pills: ETFs to Gain
Eli Lilly and Novo Nordisk are accelerating global obesity pill launches as rising GLP-1 demand puts weight-loss ETFs in focus.
6 months ago defenseworld.net
Roundhill GLP-1 & Weight Loss ETF (NASDAQ:OZEM) Short Interest Up 345.5% in April
Roundhill GLP-1 and Weight Loss ETF (NASDAQ: OZEM - Get Free Report) saw a significant increase in short interest in April. As of April 15th, there was short interest totaling 35,481 shares, an…
6 months ago marketbeat.com
3 Ways to Invest in the Growing GLP-1 Weight Loss Market
Weight loss drugs are big business, with the GLP-1 receptor agonist market expected to nearly triple in size to $185 billion by 2033, a compound annual growth rate of about 12.4%. Although…
6 months ago seekingalpha.com
Oral GLP-1 Is Here - Have Credit Markets Caught Up?
For the past two years, GLP-1 medications have been a fixture of consumer trend analysis, discussed by everyone from CNBC to sell-side strategists to management consultants. Real apparel expenditure…
8 months ago defenseworld.net
Short Interest in Roundhill GLP-1 & Weight Loss ETF (NASDAQ:OZEM) Grows By 47.1%
Roundhill GLP-1 and Weight Loss ETF (NASDAQ: OZEM - Get Free Report) was the recipient of a large increase in short interest during the month of January. As of January 30th, there was short interest…
9 months ago seekingalpha.com
OZEM Vs. THNR: Which Is The Better ETF In The GLP-1 And Weight Loss Space?
I recommend buying the Roundhill GLP-1 & Weight Loss ETF (OZEM) for strategic exposure to the weight loss drug sector. OZEM offers diversified access to leading GLP-1 innovators like Novo Nordisk and…
9 months ago feeds.benzinga.com
EXCLUSIVE: Trump 'Amplified' Several Investing Themes – ETF CEO Picks 3 Sectors Benefitting The Most
President Donald Trump may be creating investment opportunities in themes and helping put an emphasize thematic ETFs.
9 months ago benzinga.com
EXCLUSIVE: Trump 'Amplified' Several Investing Themes – ETF CEO Picks 3 Sectors Benefitting The Most
President Donald Trump may be creating investment opportunities in themes and helping put an emphasize thematic ETFs.
9 months ago marketbeat.com
Ozempic, Mounjaro, Wegovy, or Zepbound? This ETF Holds Them All
After a lackluster first half of 2025, healthcare stocks staged a comeback, posting the best performance among the 11 S&P 500 sectors over the past six months.
9 months ago etftrends.com
New Year, New Strategy: Navigating Weight Loss ETFs
With the start of 2026, the annual focus on weight loss resolutions presents a timely opportunity for financial advisors to discuss the investment potential of GLP-1 agonists with their clients. This…
10 months ago benzinga.com
Food Companies Rethink Menus For GLP-1 Users As Wegovy Weight Loss Pill Gets Approval
Food makers and restaurants adjust menus and products as GLP-1 drugs drive demand for high-protein foods and smaller portions across the U.S.
10 months ago zacks.com
6 Top-Performing ETF Areas of Last Week
Cannabis, metals, space and health care led ETF gains last week. WEED, CNBS, SIL, UFO, GDXJ, PLTM and OZEM outperformed despite tech weakness.
11 months ago benzinga.com
Novo Nordisk's Stock Slump Shows The GLP‑1 Trade's Side Effect: ETF Concentration Risk
Novo's trial setback tests GLP-1-heavy ETFs, highlighting concentration risks while Eli Lilly's diversified pipeline offers relative resilience.
1 year ago benzinga.com
Eli Lilly Extends Lead In $150B Obesity Drug Race As Novo, Pfizer Clash — Here's How ETFs Stand To Gain
As Eli Lilly, Novo Nordisk, and Pfizer battle for dominance in the obesity-drug market, these ETFs are offering exposure to the GLP-1 gold rush.
1 year ago zacks.com
5 Sector ETFs Up 10% Despite February's Market Slump
The U.S. stocks disappointed investors in Feb amid slowdown concerns and tariffs. These ETFs still gained in double digits.
-
2 years ago benzinga.com
EXCLUSIVE: Roundhill Investments Launches Weight Loss ETF For Exposure To Blockbuster Drugs Like Ozempic
Roundhill CEO Dave Mazza says investors "can't just buy a basket of big pharma names or a broad-based biotech ETF and call it a day."
-
2 years ago benzinga.com
EXCLUSIVE: GameStop, AMC Buzz 'May Prove To Be Short-Lived,' CEO Of Company Behind MEME ETF Tells Benzinga
The company behind the MEME ETF shares what it would take to bring the meme stock fund back to the market.